Vis enkel innførsel

dc.contributor.authorErtesvåg, Nina Urke
dc.contributor.authorCox, Rebecca Jane
dc.contributor.authorJalloh, Sarah Larteley Lartey
dc.contributor.authorMohn, Kristin Greve-Isdahl
dc.contributor.authorBrokstad, Karl Albert
dc.contributor.authorTrieu, Mai Chi
dc.date.accessioned2023-01-02T10:14:33Z
dc.date.available2023-01-02T10:14:33Z
dc.date.created2022-09-26T09:06:06Z
dc.date.issued2022
dc.identifier.issn2059-0105
dc.identifier.urihttps://hdl.handle.net/11250/3040244
dc.description.abstractHistory of influenza A/H3N2 exposure, especially childhood infection, shape antibody responses after influenza vaccination and infection, but have not been extensively studied. We investigated the breadth and durability of influenza A/H3N2-specific hemagglutinin-inhibition antibodies after live-attenuated influenza vaccine in children (aged 3-17 years, n = 42), and after inactivated influenza vaccine or infection in adults (aged 22-61 years, n = 42) using 14 antigenically distinct A/H3N2 viruses circulating from 1968 to 2018. We found that vaccination and infection elicited cross-reactive antibody responses, predominantly directed against newer or future strains. Childhood H3-priming increased the breadth and magnitude of back-boosted A/H3N2-specific antibodies in adults. Broader and more durable A/H3N2-specific antibodies were observed in repeatedly vaccinated adults than in children and previously unvaccinated adults. Our findings suggest that early A/H3N2 exposure and frequent seasonal vaccination could increase the breadth and seropositivity of antibody responses, which may improve vaccine protection against future viruses.en_US
dc.language.isoengen_US
dc.publisherNatureen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleSeasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 virusesen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.source.articlenumber67en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1038/s41541-022-00490-0
dc.identifier.cristin2055221
dc.source.journalnpj Vaccinesen_US
dc.relation.projectNorges forskningsråd: 284930en_US
dc.identifier.citationnpj Vaccines. 2022, 7, 67.en_US
dc.source.volume7en_US
dc.source.issue1en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal